Improved glycaemic control with biphasic insulin aspart 30 in type 2 diabetes patients failing oral antidiabetic Drugs: PRESENT study results

Abstract

Aims. This paper presents the treatment outcomes for patients intiated on biphasic insulin aspart 30 (BIAsp 30) treatment: BIAsp 30-only, BIAsp 30 + sulphonylureas (SU), BIAsp 30 + biguanides (BI), BIAsp 30 + SU + BI, BIAsp 30 + alpha-glucosidase inhibitors (GI), and BIAsp 30 + BI + thiazolidinediones (TZD) after failing oral antidiabetic drugs (OADs) treatment. Methods. This was a multi-national, multi-centre, six-month, prospective, open-labelled, uncontrolled, clinical experience evaluation study, with the exception of a three-month study in one country (China) ("all exclude China" and "China"). Initiation and discontinuation of BIAsp 30 treatment were entirely at the discretion of the attending physicians. Results. Mean HbA1c, FPG and PPPG were significantly reduced from baseline at three and six months in all groups (<0.001). In "all exclude China", reductions in mean HbA1c, FPG and PPPG at six months were as follows: BIAsp 30-only group (-2.12 ± 1.76% points; -4.82 ± 3.86mmol/L; -6.89 ± 4.74mmol/L), BIAsp 30 + BI group (-2.24 ± 1.77% points; -4.48 ± 3.68mmol/L; -6.66 ± 4.55mmol/L), BIAsp 30 + SU group (-1.95 ± 1.59% points; -3.98 ± 3.19mmol/L; -6.25 ± 4.45mmol/L) and BIAsp 30 + SU + BI group (-1.78 ± 1.20% points; -3.57 ± 2.78mmol/L; -5.89 ± 3.98 mmol/L). The only serious adverse drug reaction was reported by the BIAsp 30-only group. In the "China" group, reductions in mean HbA1c, FPG and PPPG at three months were: BIAsp 30-only group (-2.16 ± 1.52% points; -3.34 ± 2.49 mmol/L; -6.29 ± 3.92mmol/L), BIAsp 30 + BI group (-2.44 + 1.52% points; -4.01 ± 2.50mmol/L; -7.10 ± 3.96 mmol/L), BIAsp 30 + GI group (-2.33 ± 1.41% points; -4.34 ± 2.52 mmol/L; -7.97 ± 3.99mmol/L) and BIAsp 30 + BI + TZD group (-1.21 ± 1.60% points; -3.50 ± 2.29mmol/L; -5.97 ± 3.39 mmol/L). No serious ADR were reported in China. The most frequent hypoglycaemic episodes were diurnal and minor in nature. Conclusions. BIAsp 30 treatment in a clinical setting improved glycaemic control in type 2 diabetes patients failing OADs. © 2009, Archives of Drug Information.